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Previous studies have shown that the ZII element in the BZLF1 promoter (P1) is responsive to TPA and anti-immunoglobulin
induction. In this report, we have studied the DNA/protein complexes formed when ZII is used as a binding site. Twelve
distinct DNA/protein complexes were seen in mobility shift experiments using Akata cell nuclear extracts and radiolabeled
ZII. Eleven of these complexes were also formed when either BJAB or Raji cell nuclear extracts were used in the binding
reaction. Six DNA/protein complexes were affected by mutations in the core TGACATCA motif of ZII which abolish respon-
siveness to TPA, anti-immunoglobulin treatment, and HHV6 transactivation. The relative sizes of the proteins in the DNA/
protein complexes were determined by UV crosslinking. Four distinct specific binding proteins affected by core mutations
in ZII were identified as ATFa, ATF1, ATF2, and c-jun. Overexpression of ATF1 in cotransfection experiments caused
transactivation of the wild-type P1 promoter but had no effect on a promoter containing a mutant ZII element. An ATF1
mutant with a deleted DNA binding domain failed to transactivate P1. Overexpression of c-jun, ATFa, or ATF2 had no effect
on the wild-type or mutant P1 promoter. Our results suggest that ATF1 interacts with the ZII element and may be involved
in Epstein–Barr virus reactivation. q 1997 Academic Press
INTRODUCTION transactivator which is essential for the coordinate ex-
pression of viral genes characteristic of productive infec-
Epstein–Barr virus (EBV) is the etiological agent of
tion. Two promoters can be used to transcribe the BZLF1
infectious mononucleosis and is associated with a vari-
gene, P1 (Zp) and P2 (Rp). Several regulatory elementsety of cancers (Chow, 1993; Liebowitz, 1994; Niedobitek
have been identified in P1; these include three TPA re-et al., 1992; Raab-Traub, 1992). Following primary infec-
sponsive elements, designated ZIA (also an anti-immu-tion in oropharyngeal epithelial cells, EBV establishes
noglobulin response element), ZIB, and ZIC (Daibata etlatency in B lymphocytes, presumably resting B cells with
al., 1994; Flemington and Speck, 1990a; Shimizu, 1993);a CD19/CD230CD800 phenotype (Garcia-Blanco and
an AP-1 like element, ZII, which is responsive to bothCullen, 1991; Miyashita et al., 1995; Sixbey et al., 1984).
TPA and anti-immunoglobulin (Daibata et al., 1994; Flem-The persistent latent infection of EBV-infected cell lines
ington and Speck, 1990a); two ZEBRA autoregulatory ele-has made the EBV system an ideal model for the study
ments designated ZIII (Flemington and Speck, 1990b);of virus latency. Several biological and chemical agents
two distal cis-acting negative elements (Montalvo et al.,have been used to induce latent virus in infected cell
1991); and five HI motifs, also cis-acting negative regula-lines (Bauer et al., 1982; Faggioni et al., 1986; Luka et
tory elements (Schwarzmann, 1994). With the exceptional., 1979; Takada, 1984; Tovey et al., 1978; zur Hansen
of the ZIII elements (Flemington and Speck, 1990b) andet al., 1978). Among these, TPA/sodium butyrate induc-
the distal cis-acting negative regulatory elements (Mon-tion of Raji cells and anti-immunoglobulin induction of
talvo et al., 1995), little is known about the proteins whichAkata cells have been used successfully to investigate
regulate other known regulatory sites.the initial events in virus reactivation (Laux et al., 1988;
The ZII element is located 65 bp upstream of the P1Takada and Ono, 1989).
transcription start site. Mutations of the ZII site lead to aTwo viral genes, BRLF1 and BZLF1, are the first to be
dramatic decrease in both TPA and anti-immunoglobulinexpressed upon induction (Laux et al., 1988; Takada and
inducibility, suggesting that this element is a crucial pro-Ono, 1989). However, only the BZLF1 gene product ZE-
moter element (Daibata et al., 1994; Flemington andBRA (Zta) can induce lytic replication in transfected cells
Speck, 1990a). ZII contains the sequence TGACATCA(Chevallier et al., 1986; Countryman and Miller, 1985;
which resembles the binding motif for members of theTakada et al., 1986). The BZLF1 gene encodes a viral
AP-1 and CREB/ATF families. The ZII element can effi-
ciently compete for binding to AP-1 sites in the c-jun1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (210) 567-7277. E-mail: Montalvo@UTHSCSA.edu. promoter which had led to the suggestion that it is func-
323
0042-6822/97 $25.00
Copyright q 1997 by Academic Press
All rights of reproduction in any form reserved.
AID VY 8326 / 6a22$$$361 12-13-96 14:49:52 vira AP: Virology
324 WANG, HUANG, AND MONTALVO
tionally related to the c-jun AP-1 site (Flemington and sion plasmid was constructed by deleting the carboxy
terminus (amino acids 229–240) of the ATF1 DNA bind-Speck, 1990a). However, more recent data suggest that
a different transcription factor(s) regulates the ZII ele- ing domain from the pECE-ATF1 vector (see Fig. 5A). The
following oligonucleotides were synthesized as singlement (Ruf and Rawlins, 1995, Flamand and Menezes,
1996). In this report, we examined and identified cellular strands and the corresponding sequences are listed
below:proteins which bind specifically to the ZII element in
three different B-cell lines. ATFa, ATF1, ATF2, and c-
jun were identified in DNA/protein complexes. However, Z2: 5*GATCCTCCTCTGTGATGTCATGGTTTGGGACG3* and
overexpression of only one of these ZII binding proteins




Cell line, transfection procedures, and anti-
AP-1: 5*CGCTTGATGAGTCAGCCGGAA3* andimmunoglobulin induction
5*TTCCGGCTGACTCATAACGCTG3*; andAkata cells were maintained in RPMI 1640 medium
with 10% fetal bovine serum, supplemented with 50 units/ CREB: 5*AGAGATTGCCTGACGTCAGAGAGCTAG3* and
ml penicillin, 50 mg/ml streptomycin, and 2 mM L-gluta-
5*ATCGCTCTCTGACGTCAGGCAATCTCT3*.mine. For cotransfection experiments, DNA was deliv-
ered into Akata cells by electroporation. Actively growing
Anti-ATFa antibody was kindly provided by Dr. Claudecells (51 106) were suspended in 0.3 ml ice-cold medium
Kedinger; anti-c-jun/AP-1 (N), anti-ATF1 (C41-5.1), andcontaining 20 mg of the expression plasmids and 10 mg
anti-ATF2 (C-19) antibodies were purchased from Santaof the reporter plasmids in a 0.4-mm gap cuvette and
Cruz Biotechnology, Inc. Anti-ATF1 antibody (anti-p79;electroporated by a Gene Pulser apparatus (Bio-Rad) at
Hsueh and Lai, 1995) used in immunoblotting experi-0.2 kV and 960 mFD. After electroporation, cells were
ments was generously provided by Dr. Ming-Zong Laisuspended in 3 ml prewarmed medium and grown for
(Academia Sinica, Tapei, Taiwan).an additional 48 hr. For preparing anti-immunoglobulin-
induced cells, Akata cells were grown in the same me-
Mobility shift assaysdium to log phase and treated with anti-immunoglobulin
(100 mg/ml, Cappel) for 2 hr prior to nuclear extract prepa- Probes used in mobility shift experiments were either
ration (described below). labeled with [g-32P]ATP and T4 polynucleotide kinase or
[a-32P]dCTP and Klenow. Nuclear extracts were prepared
CAT assays by the Dignam method (Dignam et al., 1983). Binding
reactions were carried out by mixing 1 mg nuclear extract,After incubation, transfected cells were harvested,
1 mg poly(dI–dC), and 17.5 pg radiolabeled probe in 12washed two times in phosphate-buffered saline, and re-
mM N - 2 - hydroxyethylpiperazine - N* - 2 - ethane - sulfonicsuspended in 120 ml of 0.25 M Tris–HCl (pH 8.0). Cell
acid (HEPES), pH 7.9, 10% (vol/vol) glycerol, 5 mM MgCl2 ,lysis was carried out by three freeze–thaw cycles, and
50 mM KCl, 1 mM dithiothreitol (DTT), 50 mg/ml bovinethe debris was removed by centrifugation. For each CAT
serum albumin (BSA), 0.5 mM EDTA, and 0.05% (vol/assay, 100 ml cell lysate was mixed with 100 ml reaction
vol) Nonidet-P40 (NP-40). Competition experiments werebuffer (1.3 mM acetyl-CoA and 0.1 mCi [14C]chloram-
performed by the addition of cold competitors to the bind-phenicol in 0.25 M Tris– HCl) and incubated at 377C for
ing reactions as indicated in figure legends. Binding re-3 hr. Acetylated samples were analyzed by thin layer
actions were carried out for 20 min at ambient tempera-chromatography and the percentage acetylation was de-
ture and samples were electrophoresed on a 4% acryl-termined by a PhosphoImager CAT macro program (Mo-
amide gel in 0.251 TBE (22 mM Tris, 22 mM boric acid,lecular Dynamics, Sunnyvale, CA).
and 0.5 mM EDTA, pH 8.4). Electrophoresis was carried
out at 12.5 V/cm for 3.5 hr at 47C. For supershift experi-Plasmids, oligonucleotides, and antibodies
ments, antibodies (1 mg) were added to the reaction mix-
Plasmids p221 and pMII (Flemington and Speck, tures and incubated for an additional 20 min. After elec-
1990a) were generously provided by Dr. Samuel H. Speck trophoresis, gels were dried and exposed to XAR-5 or
(Washington University, St. Louis, MO). The ATF1 (pECE- Biomax film (Kodak).
ATF1) and ATF2 (pCGN-ATF2) expression vectors were
kindly provided by Dr. Tsonwin Hai (Ohio State University, In situ UV crosslinking
Columbus, OH). ATFa (pATFa2) and c-Jun (phcjun5) ex-
pression vectors were obtained from Dr. Claude Ked- The probe used in UV crosslinking experiments was
prepared by annealing a short synthetic oligonucleotideinger (INSERM, Cedex, France). The ATF1DDB expres-
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containing the sequence CGTCCCAAAC to the Z2(0) oli- gous ZII element competed most of the bands at 5 to 25
molar excess except for IId, IVb, and IVc. The M2 probegonucleotide and radiolabeling by the addition of Klenow
to a reaction mixture containing dATP, dGTP, BrdUTP, failed to compete any of the complexes efficiently but
competed IIIa at 100 molar excess. The consensus CREBand [a-32P]CTP (New England Nuclear). DNA binding re-
actions were carried out as described for mobility shift binding site, which contains 7 of the 8 bases found in
the core region of ZII, competed all of the complexes inassays. After electrophoresis, the gel was placed 3 cm
below a ultraviolet source in a UV crosslinker (Stra- set I, 3 of the complexes (IIa, IIb, and IIc) in set II, and
1 of the complexes (IIIb) in set III. In contrast to thetagene) and irradiated for 5 min at room temperature.
After crosslinking, the gel was exposed overnight to X- competition seen with the consensus CREB site, a con-
sensus AP-1 competitor was unable to compete for bind-ray film (XAR-5) and the visualized DNA/protein com-
plexes were excised from the gel. Gel slices were then ing to most of the complexes (even at 100 molar excess)
except for IIIb. The combined results of this experimentminced and boiled in an equal volume of 21 SDS sample
buffer for 5 min prior to loading onto a 10% SDS–PAGE. indicated that (i) AP-1 does not bind efficiently to the ZII
element when other binding proteins with higher affinityAfter electrophoresis, the gels were dried and exposed
to XAR-5 film. for the same binding site are present, (ii) 12 ZII specific
complexes are formed with the ZII probe, and (iii) 6 com-
plexes (Ia, Ib, Ic, IIa, IIb, and IIc) involve binding to theRESULTS
core TGACATCA sequence in ZII. These results were
Identification of ZII/protein complexes
consistent with a recent report describing the absence
of ZII binding by AP1 in the presence of the ZIIBC bindingThe ZII motif plays a crucial role in responsiveness to
TPA, anti-immunoglobulin, and HHV6 transactivation of complex (Ruf and Rawlins, 1995). However, our data also
suggested that there are at least 6 ZII-specific complexesBZLF1 in EBV-infected cells (Daibata et al., 1994; Fla-
mand and Menezes, 1996; Flemington and Speck, affected by mutations in the core sequence in Akata cells
which are distinct from AP1.1990a). It had been assumed that, because of an identi-
cal sequence in the c-jun promoter, AP-1 was responsi- To determine whether the 12 DNA/protein complexes
seen in Akata cells are representative of B cells in gen-ble for transactivation of the BZLF1 promoter via the ZII
element. However, two recent reports suggest that an- eral, binding experiments were also carried out with the
EBV-negative BJAB cell line and with the EBV-positiveother factor(s) other than AP1 binds to the ZII site and
transactivates BZLF1 expression (Flamand and Men- Raji cell line. The results of this experiment are shown
in Fig. 1B. In BJAB cells, 11 DNA/protein complexes wereezes, 1996; Ruf and Rawlins, 1995). Experiments were
first carried out to delineate the DNA binding proteins in resolved. Complex IIIb was absent when BJAB nuclear
cell extracts were used in the binding reaction, and com-B-cell nuclear extracts which bind to the ZII motif. For
these experiments, nuclear extracts from uninduced or plexes Ia and Ib were visible only in longer film expo-
sures. Similarly, in Raji cells 11 DNA/protein complexesinduced B cells were incubated with radiolabeled ZII
probe in the presence and in the absence of cold compet- similar to those seen in BJABs were formed. However,
the relative abundance of each complex differed amongitor DNA. Cold competitor oligonucleotides representing
the ZII element (Z2), a mutant ZII element (M2), a consen- the three cell lines, particularly the levels of IIc.
sus CREB binding site (Roesler et al., 1988), and a con-
sensus AP-1 site were tested. The results of these experi- UV crosslinking of proteins to DNA
ments are shown in Fig. 1. Four distinct sets of DNA/
protein complexes (I, II, III, and IV) representing 12 dis- UV crosslinking experiments were first carried out to
determine the approximate size of the binding protein(s)tinct complexes were seen in Akata cells with the Z2
probe (Fig. 1A). The number and relative mobility of these present in each of the DNA/protein complexes formed
with Akata cell nuclear extracts and to determinecomplexes were the same in uninduced and anti-IgG
treated cells. To determine which of these complexes whether the sizes of these proteins were consistent with
those for members of the CREB/ATF or the AP1 family.involved binding to the core TGACATCA element in the
ZII motif, similar binding reactions were carried out with For these experiments, binding reactions were done with
BrdU-labeled ZII probe and, after gel electrophoresis, thea mutant ZII probe which contains mutations that have
previously been shown to abolish responsiveness to DNA/protein complexes were crosslinked, excised, and
fractionated by SDS–PAGE. The results of this experi-TPA, anti-Ig, and HHV6 transactivation. When the M2
probe was used in the binding reactions, none of the ment are shown is Fig. 2 and summarized in Table 1. A
profile of the migration pattern with a BrdU probe isbands seen in set I were detected. In set II, 3 of the 4
complexes (IIa, IIb, and IIc) were affected by mutations shown in the left-hand side of Fig. 2. Two protein bands
corresponding to Mr 104 and 90 kDa were identified inin M2. The lower band in set II (IId) was present in M2/
protein complexes, as were all of the bands in set III and the Ia complex (lane A). Similarly, two distinct crosslinked
proteins were seen in the Ic complex corresponding toset IV. In competitive binding experiments, the homolo-
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FIG. 1. ZII/protein complexes (A) Radiolabeled Z2 probe (ZII element) or M2 probe (mutant ZII) was incubated with nuclear extract for uninduced
(0) or anti-IgG induced (/) Akata cells and the DNA/protein complexes were analyzed on a 4% nondenturing gel. Binding reactions were carried
out as described under Materials and Methods. The molar excess and name of each competitor are shown above each set of lanes. Roman
numerals and letters at the right-hand portion of the figure designate each set of DNA/protein complexes seen with the probes tested; individual
complexes are designated by lowercase letters. (B) Binding reactions were carried out with either Raji cell or BJAB cell nuclear extracts. The probes
used and designations are as described for (A).
Mr 92 and 64 kDa (lane B). In complex IIb, three bands Two of the proteins in IIb (70 and 43 kDa) were also
seen in complex IIc (lane D). A prominent band with anwere resolved. The relative molecular weights of these
proteins were 70, 48, and 43 kDa, respectively (lane C). Mr of 64 kDa and a weaker band of Mr 92 kDa were
found in complex IIIa (lane E). Complex IVb contained
two crosslinked proteins with Mr 46 and 52 kDa (lane F)
whereas a strong band of Mr 36 kDa and a weaker 24-
kDa band were seen in complex IVc (lane G). The pro-
teins in the Ib, IIa, IId, IIIb, and IVa complexes could not
be identified because these complexes were either very
weak or indiscernible when a BrdU probe was used in
the binding reaction.
ATF1, ATFa, ATF2, and c-jun bind the ZII element
To begin to address the identification of the cross-
linked proteins, supershift experiments were performed
with antibody specific for members of either the ATF/
CREB family or the AP1 family. Binding reactions wereFIG. 2. UV crosslinking of ZII binding proteins. A BrdU-substituted
carried out with uninduced or induced Akata cell nuclearradiolabeled ZII probe was incubated with Akata cell nuclear extracts.
After nondenaturing gel electrophoresis, the DNA/protein complexes extracts and, after 20 min, antibody or an equivalent
were crosslinked, excised, and subjected to SDS–PAGE as described amount of buffer was added to the samples. Anti-c-jun
under Materials and Methods. A profile of the BrdU-substituted DNA/ supershifted the lower band seen in set I (Ic) and ap-
protein complexes in a nondenaturing gel is seen at the left-hand side
peared to enhance the formation of the Ia complex (Fig.of the figure. The sizes of the molecular weight standards are shown
3). Anti-ATFa also supershifted the Ic complex. In addi-on the left and the letter corresponding to the excised complex is
shown at the top of each lane. tion, the mobility of the upper Ia complex was slightly
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TABLE 1
Complex Akata Raji BJAB M2 probe binding Mr (kDa) Protein identified
Ia / / / No 104 and 90 —
Ib / / / No NDa ATF2
Ic / / / No 92 and 64 c-jun, ATF2, & ATFa
IIa / / / No ND —
IIb / / / No 70, 48, and 43 ATF1
IIc / / / No 70 and 43 ATF1
IId / / / Yes ND —
IIIa / / / Yes 64 and 92 —
IIIb / 0 0 Yes ND —
IVa / / / Yes ND —
IVb / / / Yes 46 and 52 —
IVc / / / Yes 36 and 24 —
a ND, Not determined.
altered by the presence of anti-ATFa in the binding reac- These experiments suggested that c-jun, ATFa, ATF1,
and ATF2 are present in at least four of the six complexestion but it was difficult to determine whether this repre-
sented antibody binding to the complex. Anti-ATF1 anti- affected by mutations introduced into the M2 probe.
body supershifted the two bands (IIb and IIc) in set II
complexes. It was difficult to determine whether any com- ATF1 transactivates the P1 promoter
plexes in set I were affected by the presence of anti-
ATF1 antibody since the supershifted complexes inter- Overexpression of several transcription factors have
fered with the resolution of these complexes. Antibody been shown to transactivate natural promoters con-
specific for ATF2 was also tested in these experiments. taining the TGACATCA motif found in the ZII element of
Anti-ATF2 supershifted complexes Ib and Ic (Fig. 3B). the BZLF1 promoter. Overexpression of c-jun has been
found to transactivate the c-jun promoter (Angel et al.,
1988), ATFa transactivates the E-selectin promoter (Kas-
zubska et al., 1993), and a murine isoform of ATF2 is
involved in regulation of the CD3d gene promoter (Geor-
gopoulos et al., 1992). Since ATFa, ATF1, ATF2, and c-
jun supershifted ZII specific complexes, cotransfections
were carried out with plasmids expressing these tran-
scription factors. The results of these experiments are
shown in Fig. 4A. Overexpression of c-jun and ATFa,
which have previously been shown to act on a sequence
identical to that present in the ZII element, had no effect
on either the wild-type promoter (p221) or a promoter
containing mutations at the ZII site. Similarly, ATF2 had
no effect on P1 promoter activity. Surprisingly, overex-
pression of ATF1 was sufficient to cause a 20-fold in-
crease in the expression of the wild-type promoter. How-
ever, ATF1 had no effect on pMII, a BZLF1 promoter
containing specific point mutations which abolish re-
sponsiveness to TPA and anti-immunoglobulin.
To confirm that the proteins encoded by the trans-
fected plasmid were overexpressed in transfected cells,
Western blot experiments were carried out using specific
FIG. 3. Identification of ZII binding proteins. Nuclear extracts from antibody. Of the proteins tested (c-jun, ATFa, ATF1, and
Akata cells were mixed with radiolabeled Z2 probe and binding reac- ATF2), all were overexpressed in transfected cells (Fig.
tions were carried out as described under Materials and Methods. 4B). Combined with the binding data, these results sug-
After a 20-min incubation, antibody was added and samples were incu-
gested that (1) overexpressed ATF1 transactivates thebated for an additional 20 min. The absence (0) or presence (/) of
BZLF1 promoter and (2) transactivation is mediatedextract is indicated at the top of the figure. The antibody used in each
supershift experiment is shown above each pair of lanes. through the core region of the ZII element since muta-
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treatment (Daibata et al., 1994; Flemington and Speck,
1990a). In this report we have investigated the ZII binding
proteins and have identified six ZII-specific DNA/protein
complexes which are affected by mutations in the core
region of the ZII element known to abolish respon-
siveness to TPA, anti-immunoglobulin, and HHV6 trans-
activation. Four of the proteins in these six complexes
were identified by supershift experiments as c-jun, ATFa,
ATF1, and ATF2. In addition, several novel DNA binding
proteins which do not correspond to the molecular
weights of known members of the CREB/ATF or AP1
family were identified in DNA/protein complexes by
crosslinking experiments.
Although 12 DNA/protein complexes were formed with
the ZII probe, 6 of these are unaffected by specific muta-
tions in the TGACATCA core of ZII, which most likely affect
virus latency. Therefore, a subset of the DNA binding pro-
teins identified by UV crosslinking are unlikely to be in-
volved EBV latency/reactivation. All 6 mutation-sensitive
complexes (Ia, Ib, Ic, IIa, IIb, and IIc) were seen with the
3 different B-cell lines used in this study. Ia contains 2
novel proteins of Mr 104 and 90 kDa. Ic contained a novel
92-kDa binding protein and a 64-kDa protein, either ATFa
or ATF2. Although antibodies to c-jun also supershift this
FIG. 4. ATF1 transactivates the BZLF1 P1 promoter. (A) p221 or pMII
was cotransfected with plasmids expressing ATFa, ATF1, ATF2, or c-
jun by electroporation as described under Materials and Methods. After
48 hr, the cells were harvested and CAT assays were performed. CAT
activity was determined using a macro program from Molecular Dynam-
ics. Each bar represents the average of three independent experiments
carried out with three different preparations of DNA. The designation
of the reporter plasmid is given at top right corner and the transactivator
tested in each cotransfection is given below each pair of samples. (B)
Representative thin layer chromatography of CAT activity in cotransfec-
tion experiment. (C) Western analyses of transfected cells. 20 mg of
plasmid was transfected into Akata cells and after 24 hr, extracts were
prepared. 25 mg of protein extract was fractionated by SDS–PAGE,
transferred to nitrocellulose, and probed with specific antibody. Pro-
teins bound by specific antibody were detected by enhanced chemilu-
minescence (ECL, Amersham).
tions which abolish ATF1 binding also affect the ability
of ATF1 to transactivate.
Experiments were then carried out to determine
whether ATF1 binding was necessary for transactivation.
An ATF1 mutant, ATF1DDB, was tested in these experi-
ments. ATF1DDB contains a deletion of the DNA binding
motif with retention of the dimerization domain (Fig. 5A).
The results of cotransfection experiments and the levels
of overexpressed protein are shown in Figs. 5B and 5C,
respectively. ATF1DDB failed to transactivate the BZLF1
promoter although the mutant was overexpressed to lev-
FIG. 5. DNA binding is necessary for transactivation. Expressionels comparable to those of the wild-type protein. These
plasmids were cotransfected with p221 into Akata cells. After 48 hr,experiments suggested that ATF1 binding is necessary
cells were harvested and CAT assays were carried out as describedfor transactivation of P1.
under Materials and Methods. (A) Schematic representation of ATF1
expression plasmids used in transfections. (B) Transfection with vectorDISCUSSION
control, ATF1, or ATF1DDB as designated in the figure. The amounts
The ZII element in the EBV BZLF1 P1 promoter is shown are the average of three independent experiments. (C) Expres-
sion of protein in transfected cells.known to be responsive to TPA and anti-immunoglobulin
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complex, no bands corresponding to the size of c-jun were contains mutations known to affect TPA and anti-immu-
noglobulin inducibility of ZII. Consistent with the bindingseen in crosslinking experiments. Complexes IIb and IIc
contained a novel 70-kDa binding protein and a 43-kDa data, overexpression of ATF1 transactivates the wild-type
promoter but has no effect on a promoter containingprotein. Based on supershift experiments, the 43-kDa pro-
tein is ATF1. An additional 48-kDa band was seen in IIb, mutations within the core region of ZII. Further evidence
for ATF1 involvement is the failure of a mutant ATF1which is consistent with the molecular weight of CREB.
Since CREB has previously been found in ZII-specific com- (deleted DNA binding domain) to transactivate the wild-
type promoter. Taken together, these data suggest thatplexes by other investigators, it is conceivable that the
CREB is also present in complex IIb. ATF1 transactivates the P1 promoter by binding to the
ZII element. A caveat is that the endogenous levels ofA previous report described a novel ZII binding com-
plex, ZIIBC, which is presumably involved in transcrip- ATF1 are insufficient for BZLF1 transactivation despite
ATF1 binding in uninduced extracts.tional regulation of the BZLF1 promoter (Ruf and Rawlins,
1995). Based on specific binding to ZII, the absence of We do not currently know why overexpression of ATF1
in the absence of other inducers causes such an efficientbinding to a mutant ZII site, and slight mobility differ-
ences between DNA/protein complexes formed with ex- transactivation of the BZLF1 promoter. The current data
suggest that transactivation is not caused by changes intracts from uninduced and induced cells, it was sug-
gested that ZIIBC plays a critical role in EBV reactivation. the intracellular levels of heterodimer/homodimer among
members of the ATF/CREB family since a mutant ATF1One of the complexes (IVC) described in this study con-
tained proteins of 36 and 24 kDa which closely resemble which retains the dimerization domain failed to transacti-
vate the P1 promoter. Furthermore, we have not beenthe proteins in the ZIIBC complex (36 and 26 kDa). How-
ever, the formation of the IVC complex was unaffected able to determine whether ATF1 is absolutely essential
for EBV reactivation. Despite numerous attempts andby the same ZII core mutations which presumably affect
ZIIBC complex formation. strategies, we have been unable to reduce the levels of
endogenous ATF1 with either antisense oligonucleotideThe TGACATCA sequence found in the ZII element
technology or vectors expressing antisense RNA to ATF1.has now been found in several natural promoters includ-
It should be noted, however, that resting cells are pre-ing the c-jun promoter (Angel, 1988), the E-selectin pro-
sumably the natural reservoir for latent EBV and thatmoter (Kaszubska et al., 1993), and the promoters for
ATF1 is induced in resting lymphocytes by phorbol esterthree T-cell receptor (TCR) genes, a, b, and CD3d genes
and calcium ionophore, two agents known to activate(Georgopoulos et al., 1992; Leiden, 1993). Overex-
latent EBV (Hsueh and Lai, 1995). Thus, ATF1 should bepression of c-jun has been shown to transactivate the c-
considered a potential activator of EBV reactivation.jun promoter but had no effect on BZLF1 promoter activity
ATF1 is now the second identified cellular proteinin Akata cells. Our results are consistent with previous
shown to both bind ZII and transactivate the BZLF1 pro-data describing similar experiments in the Ramos cell
moter in vitro. The other is CREB, which has recentlyline (Flemington and Speck, 1990a). In the E-selectin pro-
been reported to be involved in cAMP-dependent activa-moter, this sequence, referred to as the NF-ELAM1 site,
tion by HHV-6 (Flamand and Menezes, 1996). However,is an IL-1 inducible element which requires an interaction
the studies implicating CREB as a potential regulator ofbetween NF-kB and ATFa. ATFa binds to the NF-ELAM1
EBV reactivation were carried out in Jurkat cells, a T-cellelement and transactivates the E-selectin promoter (Kas-
line. Furthermore, inducers of cAMP are not known tozubska et al., 1993). The BZLF1 promoter contains no
induce latent EBV into lytic replication. In addition to ATF1known NF-kB sites and, although ATFa binds to the ZII
and CREB, the ZIIBC complex has also been reported toelement, no transactivation was observed in cotransfec-
specifically bind the core region of ZII and to transacti-tion experiments. In the T-cell receptor CD3d gene pro-
vate BZLF1 promoter activity. Unfortunately, none ofmoter, a CRE in the dA element of the CD3d promoter is
these factors have been shown to induce BZLF1 expres-unresponsive to changes in cAMP but is responsive to
sion in latently infected cells. The identification of a tran-CRE-BP2, an isoform of murine ATF2 which differs at the
scription factor(s) which both binds the ZII core and af-amino terminus. We have tested the human ATF2 which
fects promoter activity is a necessary and important stephad no effect on BZLF1 promoter activity. A more recent
toward delineating the molecular mechanisms of Ep-candidate for transactivation at ZII is the phosphorylated
stein–Barr virus latency. However, although these fac-CREB protein which was found to transactivate the P1
tors can affect BZLF1 promoter activity in vitro, it may bepromoter in Jurkat cells when PKA was also coexpressed
necessary to disrupt endogenous expression of these(Flamand and Menezes, 1996). We have also tested
transcription factors before their significance in EBV la-CREB in B-cell cotransfection experiments (data not
tent/lytic replication can be determined.shown) but only a minimal effect is seen in the absence
of PKA consistent with the effects previously shown in ACKNOWLEDGMENTS
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